Revolution Medicines, Inc. (RVMD) Stock

Revolution Medicines, Inc. (RVMD) is a Healthcare stock trading at $186.00 (as of 2026-07-17), with a market capitalization of $39.54B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Revolution Medicines, Inc. is a clinical-stage precision oncology company developing targeted therapies aimed at RAS-addicted cancers. Its pipeline includes inhibitors such as SHP2, SOS1, and mTORC1 signaling, along with mutant- and RAS-variant specific KRAS and NRAS inhibitors, for solid tumor patients.

Understand Revolution Medicines, Inc.: how it makes money

Revolution Medicines develops precision oncology therapies aimed at RAS-addicted cancers, and it generates revenue primarily from collaborations (including a Sanofi SHIP-2 collaboration and other Sanofi collaboration revenue items).

Because product revenue is not yet evident (latest-quarter revenue is 0.0B), the economics of the business are driven by clinical progress and the associated collaboration outcomes rather than by selling an approved therapy.

Revenue by segment (latest quarter)
Sanofi SHIP-2 collab$0.0B
Sanofi collab (terminated)$0.0B

Business quality (Weak): Clinical-stage precision oncology with collaboration revenue at 0.0B in the latest quarter, so near-term fundamentals hinge on trial results and tolerability signals.

Bull case

  • Multiple active development programs in RAS biology: The company is developing RMC-4630 (SHP2 inhibitor) in Phase 1/2 for solid tumors, and it also develops RMC-5845 (SOS1 inhibitor) and RMC-5552 (mTORC1 signaling inhibitor), plus other programs including RMC-6291.
  • Encouraging anti-tumor activity signals in reported studies: Reported objective response and disease control metrics include RMC9805 objective response rate of 30% and disease control rate of 80%, and RMC6236 disease control rate of 87%.
  • Broad clinical footprint: The company reports 8 randomized Phase 3 registrational trials and 4 clinical-stage investigational drugs.

Bear case

  • Tolerability may be a concern: Reported safety includes 96% any-grade treatment-related adverse events and 22% Grade 3 or higher treatment-related adverse events.
  • Revenue is 0.0B in the latest quarter: For the period 2026-03-31, revenue is reported as 0.0B, with operating margin reported at -2282.3.
  • Collaboration dynamics can shift: The company reports Sanofi collaboration revenue (terminated), which suggests collaboration-related cash flows may not be stable.
Valuation — source: SEC EDGAR (first-party)
Price$186.00
Market Cap$39.54B
Price / Book26.36
Price / Sales444.75
FCF Yield-4.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$0.00
Revenue Growth (YoY)-100.0%
EPS Growth (YoY)-7.3%
FCF Growth (YoY)58.5%
Financial Health — source: SEC EDGAR
Altman Z-Score28.13 (safe)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.4
Industry P/E (Pharmaceutical Products)17.1
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($1.33B)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMark A. Goldsmith
Employees616
CountryUS
IPO Date2020-02-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Moderna, Inc. (MRNA)
  • Exelixis, Inc. (EXEL)
  • Krystal Biotech, Inc. (KRYS)
  • Apogee Therapeutics, Inc. (APGE)
  • Kymera Therapeutics, Inc. (KYMR)
  • Halozyme Therapeutics, Inc. (HALO)
  • Vaxcyte, Inc. (PCVX)
  • ImmunityBio, Inc. (IBRX)
RVMD earnings history · RVMD institutional & insider holders · RVMD KPIs & operating metrics · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-07-17.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.